What is IMRX stock price today?

IMRX (Immuneering Corp) stock is trading at $5.70 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is IMRX stock going up or down today?

IMRX stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy IMRX stock now?

The decision to buy IMRX depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is IMRX a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for IMRX based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is IMRX stock overvalued or undervalued?

Use our DCF valuation calculator to determine if IMRX is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is IMRX's P/E ratio?

P/E ratio data for IMRX will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is IMRX's market cap?

IMRX (Immuneering Corp) has a market capitalization of $0.36 billion, making it a small-cap stock.

What is IMRX's price to book ratio?

IMRX trades at a price-to-book (P/B) ratio of 1.63, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does IMRX pay dividends?

IMRX does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is IMRX's dividend yield?

IMRX does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is IMRX stock a good long-term investment?

IMRX's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is IMRX's revenue growth rate?

IMRX has shown revenue growth of -1.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for IMRX are available on our dashboard with complete income statement analysis.

What are the risks of investing in IMRX?

Key risks for IMRX include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does IMRX compare to its competitors?

Compare IMRX to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize IMRX's performance and positioning.

What is IMRX's stock price target for 2026?

Our AI model provides price targets for IMRX based on fundamental analysis: Bull case $7.41 (+30%), Base case $6.55 (+15%), Bear case $5.13 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about IMRX?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for IMRX. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is IMRX's next earnings report?

IMRX reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

IMRX - Immuneering Corp

NYSE * Health Care * Biotechnology

$5.70

+$0.18 (+3.26%)

About Immuneering Corp

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

IMRX Key Statistics

Market Cap

$356.88M

P/B Ratio

1.63

EPS

$-1.27

Revenue Growth

-1.0%

Employees

How IMRX Compares to Peers

IMRX is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
IMRX(This stock)	$356.88M	N/A	-1%	0.0%	-
AMGNAmgen Inc	$189.22B	24.7	0%	0.2%	vs AMGN
GILDGilead Sciences	$172.51B	20.5	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$110.97B	28.5	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.17B	18.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$25.38B	19.7	-0%	0.1%	vs BIIB

Immuneering Corp Company Information

Headquarters: Massachusetts; U.S.A
Website: immuneering.com
Sector: Health Care
Industry: Biotechnology

IMRX - Immuneering Corp

About Immuneering Corp

IMRX Key Statistics

How IMRX Compares to Peers

Immuneering Corp Company Information

IMRX Lician Score

IMRX Financial Snowflake

Upcoming Events for IMRX